Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients with Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region

被引：0
|
作者：
Khadadah, Fatima [1 ]
Cherif, Honar [2 ]
El Omri, Halima [3 ]
Absi, Ahmed [4 ]
Merwass, Noor [5 ]
Abu Haleeqa, Mohamed I. [6 ]
Jaber, Waed [6 ]
Alhuraiji, Ahmad [7 ]
Pandita, Ramesh [1 ]
机构：
[1] Kuwait Canc control Ctr, Kuwait, Kuwait
[2] Natl Ctr Canc Care & Res, Hematol BMT, Doha, Qatar
[3] Hamad Univ, Ar Rayyan, Qatar
[4] Natl Guard Hlth Affairs, Princess Noorah Oncol Ctr, King Abdulaziz Med City Western Reg, Jeddah, Saudi Arabia
[5] Minist Natl Guard Hlth Affairs, Dept Adult Hematol & Stem Cell Transplantat, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia
[6] Sheikh Shakhbout Med Ctr, Abu Dhabi, U Arab Emirates
[7] Kuwait Canc Ctr, Shuwaikh, Kuwait
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181520
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital
    Khan, Hina
    Yohannan, Binoy
    Cervoni-Curet, Frances
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S262 - S262
  • [32] VENETOCLAX AND AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES, A REAL-WORLD EXPERIENCE. LATIN-AMERICAN MDS GROUP - GLAM
    Iastrebner, M.
    Crisp, R.
    Ovilla, R.
    Enrico, A.
    Gomez De Leon, A.
    Varela, A.
    Velloso, E.
    Puente, A.
    Duarte, F.
    Moreno Gusmao, B.
    Schusterschitz, S.
    Wernicke, P.
    Boada, M.
    Pereyra, P.
    Grille, S.
    LEUKEMIA RESEARCH, 2023, 128
  • [33] Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications
    Donnellan, William
    Xu, Tao
    Ma, Esprit
    Jin, Huan
    Montez, Melissa
    Choi, Michelle
    Ku, Grace
    Rajeswaran, Raj Anand
    Ramsingh, Giridharan
    Flahavan, Evelyn M.
    BLOOD, 2020, 136
  • [34] Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Ma, Xiaomei
    Swern, Arlene S.
    Kiselev, Pavel
    Fliss, Albert
    Lu, Jane J.
    Scott, Bart L.
    Steensma, David P.
    Sugrue, Mary M.
    BLOOD, 2015, 126 (23)
  • [35] Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
    Bewersdorf, Philipp
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Ramaswamy, Rahul
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Gurnari, Carmelo
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [36] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Zimmerman, Cassie
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Jabbour, Elias
    Kantarjian, Hagop
    Zell, Katrina
    Wang, Quiqing
    Gore, Steven D.
    Nazha, Aziz
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [37] High burden and poor outcomes of myelodysplastic neoplasms (MDS) in the real-world: a 10-year audit of three Australian hospitals
    Loh, Zoe
    Ashby, Michael
    Rahman, Marzia
    Wong, Evangeline Y.
    Ong, Doen Ming
    Morgan, Susan
    Chua, Chong Chyn
    LEUKEMIA & LYMPHOMA, 2025,
  • [38] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
    Ong, Faustine
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Ohanian, Maro
    Konopleva, Marina
    Jabbour, Elias
    Jain, Nitin
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval
    Issa, Ghayas C.
    Sasaki, Koji
    Chien, Kelly S.
    Takahashi, Koichi
    Andreeff, Michael
    Muftuoglu, Muharrem
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Kantarjian, Hagop
    Cortes, Jorge E.
    Short, Nicholas
    BLOOD, 2022, 140 : 6206 - 6208
  • [39] REAL WORLD DATA CONFIRMS ACTIVITY OF LUSPATERCEPT IN HIGHER RISK AND HYPOMETHYLATING AGENTS-FAILED PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    Gong, Y.
    He, G.
    LEUKEMIA RESEARCH, 2023, 128
  • [40] Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US
    Vachhani, Pankit
    Ma, Esprit
    Xu, Tao
    Montez, Melissa
    Worth, Sarah
    Cheng, Wei-Han
    Werner, Michael
    Abbas, Jonathan
    Donnellan, William
    BLOOD, 2022, 140
12345